

- 2 Oji V, Tadini G, Akiyama M *et al.* Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. *J Am Acad Dermatol* 2010; **63**:607–41.
- 3 Mazereeuw-Hautier J, Vahlquist A, Traupe H *et al.* Management of congenital ichthyoses: European guidelines of care, part one. *Br J Dermatol* 2019; **180**:272–81.
- 4 Mazereeuw-Hautier J, Hernández-Martín A, O'Toole EA *et al.* Management of congenital ichthyoses: European guidelines of care, part two. *Br J Dermatol* 2019; **180**:484–95.
- 5 Vernooij RWM, Alonso-Coello P, Brouwers M *et al.* Reporting items for updated clinical guidelines: Checklist for the Reporting of Updated Guidelines (CheckUp). *PLOS Med* 2017; **14**:e1002207.
- 6 Küster W, Bohnsack K, Rippke F *et al.* Efficacy of urea therapy in children with ichthyosis. A multicenter randomized, placebo-controlled, double-blind, semilateral study. *Dermatology* 1998; **196**:217–22.
- 7 Tadini G, Giustini S, Milani M. Efficacy of topical 10% urea-based lotion in patients with ichthyosis vulgaris: a two-center, randomized, controlled, single-blind, right-vs.-left study in comparison with standard glycerol-based emollient cream. *Curr Med Res Opin* 2011; **27**:2279–84.
- 8 Kempers S, Katz HI, Wildnauer R, Green B. An evaluation of the effect of an alpha hydroxy acid-blend skin cream in the cosmetic improvement of symptoms of moderate to severe xerosis, epidermolytic hyperkeratosis, and ichthyosis. *Cutis* 1998; **61**:347–50.
- 9 Gånemo A, Virtanen M, Vahlquist A. Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulations. *Br J Dermatol* 1999; **141**:1027–32.
- 10 Pope FM, Rees JK, Wells RS, Lewis KG. Out-patient treatment of ichthyosis: a double-blind trial of ointments. *Br J Dermatol* 1972; **86**:291–6.
- 11 Buxman M, Hickman J, Ragsdale W *et al.* Therapeutic activity of lactate 12% lotion in the treatment of ichthyosis. Active versus vehicle and active versus a petrolatum cream. *J Am Acad Dermatol* 1986; **15**:1253–8.
- 12 Dorf ILH, Lunen MS, Koppelhus U. Effect of topical treatment with 7.5% urea in ichthyosis vulgaris: a randomized, controlled, double blinded, split body study evaluating the effect of urea cream compared to the vehicle (moisturizing) cream. *Skin Health Dis* 2021; **1**:e65.
- 13 Celleno L. Topical urea in skincare: a review. *Dermatol Ther* 2018; **31**:e12690.
- 14 Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. *J Invest Dermatol* 2008; **128**:1728–36.
- 15 Madan RK, Levitt J. A review of toxicity from topical salicylic acid preparations. *J Am Acad Dermatol* 2014; **70**:788–92.
- 16 Chiaretti A, Schembri Wismayer D, Tortorolo L *et al.* Salicylate intoxication using a skin ointment. *Acta Paediatr* 1992 1997; **86**:330–1.
- 17 Ramírez ME, Youseef WF, Romero RG *et al.* Acute percutaneous lactic acid poisoning in a child. *Pediatr Dermatol* 2006; **23**:282–5.
- 18 Ward PS, Jones RD. Successful treatment of a harlequin fetus. *Arch Dis Child* 1989; **64**:1309–11.
- 19 Germann R, Schindera I, Kuch M *et al.* [Life-threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris]. *Hautarzt* 1996; **47**:624–7 (in German).
- 20 Galea P, Goel KM. Salicylate poisoning in dermatological treatment. *Arch Dis Child* 1990; **65**:335.
- 21 Leibson T, Davies P, Nickel C, Koren G. Hyperosmolar metabolic acidosis in burn patients exposed to glycol based topical antimicrobials – a systematic review. *Burns* 2018; **44**:776–83.
- 22 Garty BZ. High plasma urea concentration in babies with lamellar ichthyosis. *Arch Dis Child* 1986; **61**:1245–6.
- 23 Beverley DW, Wheeler D. High plasma urea concentrations in collodion babies. *Arch Dis Child* 1986; **61**:696–8.
- 24 Kragballe K, Steijlen PM, Ibsen HH *et al.* Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. *Arch Dermatol* 1995; **131**:556–60.
- 25 Paller AS, Browning J, Parish LC *et al.* Safety, tolerability, and efficacy of a novel topical isotretinoin formulation for the treatment of X-linked or lamellar congenital ichthyosis: results from a phase 2a proof-of-concept study. *J Am Acad Dermatol* 2022; **87**:1189–91.
- 26 Marathe K, Teng JMC, Guenther S *et al.* Topical isotretinoin (TMB-001) treatment for 12 weeks did not result in clinically relevant laboratory abnormalities in participants with congenital ichthyosis in the phase 2b CONTROL study. *Dermatol Ther* 2023; **13**:1255–64.
- 27 Hofmann B, Stege H, Ruzicka T, Lehmann P. Effect of topical tazarotene in the treatment of congenital ichthyoses. *Br J Dermatol* 1999; **141**:642–6.
- 28 Virtanen M, Gedde-Dahl T, Mörk NJ *et al.* Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression. *Acta Derm Venereol* 2001; **81**:163–70.
- 29 Cotellessa C, Cuevas-Covarrubias SA, Valeri P *et al.* Topical tazarotene 0.05% versus glycolic acid 70% treatment in X-linked ichthyosis due to extensive deletion of the *STS* gene. *Acta Derm Venereol* 2005; **85**:346–8.
- 30 Niculescu L, Ruini C, Srouf J *et al.* Tazarotene 0.015% cream as a potential topical agent for management of ichthyosis in Dorfman–Chanarin syndrome. *Acta Derm Venereol* 2019; **99**:345–6.
- 31 Behera B, Chandrashekar L, Singh N *et al.* Lamellar ichthyosis associated bilateral pseudoainhum of fingers and toes successfully treated with tazarotene. *Dermatol Ther* 2017; **30**:e12516.
- 32 Kundu RV, Garg A, Worobec SM. Lamellar ichthyosis treated with tazarotene 0.1% gel. *J Am Acad Dermatol* 2006; **55** (5 Suppl.):S94–5.
- 33 Marulli GC, Campione E, Chimenti MS *et al.* Type I lamellar ichthyosis improved by tazarotene 0.1% gel. *Clin Exp Dermatol* 2003; **28**:391–3.
- 34 Stege H, Hofmann B, Ruzicka T, Lehmann P. Topical application of tazarotene in the treatment of nonerythrodermic lamellar ichthyosis. *Arch Dermatol* 1998; **134**:640–1.
- 35 Yoo S, Simzar S, Han K *et al.* Erythrokeratoderma variabilis successfully treated with topical tazarotene. *Pediatr Dermatol* 2006; **23**:382–5.
- 36 Barbarot S, Acher-Chenebaux A, Stalder J-F. [Topical tazarotene for severe congenital ichthyosis]. *Ann Derm Venereol* 2006; **133**:66–7 (in French).
- 37 Rajiv S, Rakshesh SV. Ichthyosis bullosa of Siemens: response to topical tazarotene. *Indian J Dermatol Venereol Leprol* 2006; **72**:43–6.
- 38 Hanson B, Becker L, Hook K *et al.* Ectropion improvement with topical tazarotene in children with lamellar ichthyosis. *Pediatr Dermatol* 2017; **34**:584–9.
- 39 Nguyen V, Cunningham BB, Eichenfield LF *et al.* Treatment of ichthyosisiform diseases with topically applied tazarotene: risk of systemic absorption. *J Am Acad Dermatol* 2007; **57** (5 Suppl.):S123–5.
- 40 Ogawa M, Akiyama M. Successful topical adapalene treatment for the facial lesions of an adolescent case of epidermolytic ichthyosis. *J Am Acad Dermatol* 2014; **71**:e103–5.
- 41 Kaplan YC, Ozsarfati J, Etwel F *et al.* Pregnancy outcomes following first-trimester exposure to topical retinoids: a systematic review and meta-analysis. *Br J Dermatol* 2015; **173**:1132–41.
- 42 Buchan P, Eckhoff C, Caron D *et al.* Repeated topical administration of all-*trans*-retinoic acid and plasma levels of retinoic acids in humans. *J Am Acad Dermatol* 1994; **30**:428–34.